These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 803104)

  • 21. Primary dexamethasone treatment of multiple myeloma.
    Alexanian R; Dimopoulos MA; Delasalle K; Barlogie B
    Blood; 1992 Aug; 80(4):887-90. PubMed ID: 1498331
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Letter: Treatment of myeloma.
    Jacobs P; Dubovsky D
    Br Med J; 1975 Mar; 1(5958):625. PubMed ID: 1125634
    [No Abstract]   [Full Text] [Related]  

  • 23. Superior efficacy of MMCP regimen compared with VMCP and MMPP regimens in the treatment of multiple myeloma.
    Mizuno H; Yamao H; Nagura E; Shimizu K; Kamiya O; Takeyama H; Nitta M; Wakita A; Ichikawa A; Kobayashi M; Kawashima K; Saito H;
    Intern Med; 2002 Apr; 41(4):290-4. PubMed ID: 11993789
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The treatment of multiple myeloma.
    Alexanian R; Dimopoulos M
    N Engl J Med; 1994 Feb; 330(7):484-9. PubMed ID: 8289856
    [No Abstract]   [Full Text] [Related]  

  • 25. Combination chemotherapy for multiple myeloma with BCNU, cyclophosphamide, vincristine, melphalan, and prednisone (M-2 protocol).
    Case DC; Sonneborn HL; Paul SD; Hayes DM; Dorsk BM; Carroll RJ; Bove L
    Oncology; 1985; 42(3):137-40. PubMed ID: 3858763
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment of multiple myeloma: 2009 update.
    Prescrire Int; 2009 Dec; 18(104):263-6. PubMed ID: 20025098
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Standard-dose therapy for multiple myeloma: The Southwest Oncology Group experience.
    Crowley J; Jacobson J; Alexanian R
    Semin Hematol; 2001 Jul; 38(3):203-8. PubMed ID: 11486307
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Improved survival times in multiple myeloma treated with melphalan, prednisone, cyclophosphamide, vincristine and BCNU: M-2 protocol.
    Case DC; Lee DJ; Clarkson BD
    Am J Med; 1977 Dec; 63(6):897-903. PubMed ID: 605911
    [No Abstract]   [Full Text] [Related]  

  • 29. Objective evaluation of the role of vincristine in induction and maintenance therapy for myelomatosis. Medical Research Council Working Party on Leukaemia in Adults.
    MacLennan IC; Cusick J
    Br J Cancer; 1985 Aug; 52(2):153-8. PubMed ID: 3896288
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cell kinetics and therapy in multiple myeloma: an update of the M83 protocol.
    Pileri A; Barbui T; Boccadoro M; Comotti B; Dammacco F; Gallamini A; Marmont F; Neretto G; Petrucci MT; Resegotti L
    Bone Marrow Transplant; 1989 Jan; 4 Suppl 1():168-9. PubMed ID: 2713554
    [No Abstract]   [Full Text] [Related]  

  • 31. Early plasma cell recruitment in multiple myeloma following chemotherapy.
    Ucci G; Riccardi A; Dörmer P; Danova M; Luoni R
    Cell Tissue Kinet; 1988 Nov; 21(6):405-9. PubMed ID: 3251633
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Drug - resistant multiple myeloma. A trial with the M 2 cyclic alkylating agent polychemotherapy.
    Buonanno G; Tortarolo M; Valente A; Castaldo C; Russolillo S; Gonnella F
    Haematologica; 1978 Feb; 63(1):45-55. PubMed ID: 417971
    [No Abstract]   [Full Text] [Related]  

  • 33. [Plasmocytic pleural effusion disclosing multiple myeloma].
    Elloumi M; Frikha M; Masmoudi H; Mseddi S; Ben Ayed M; Bouaziz M; Makni F; Souissi T
    Rev Mal Respir; 2000 Apr; 17(2):495-7. PubMed ID: 10859769
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study.
    Cavo M; Gay F; Beksac M; Pantani L; Petrucci MT; Dimopoulos MA; Dozza L; van der Holt B; Zweegman S; Oliva S; van der Velden VHJ; Zamagni E; Palumbo GA; Patriarca F; Montefusco V; Galli M; Maisnar V; Gamberi B; Hansson M; Belotti A; Pour L; Ypma P; Grasso M; Croockewit A; Ballanti S; Offidani M; Vincelli ID; Zambello R; Liberati AM; Andersen NF; Broijl A; Troia R; Pascarella A; Benevolo G; Levin MD; Bos G; Ludwig H; Aquino S; Morelli AM; Wu KL; Boersma R; Hajek R; Durian M; von dem Borne PA; Caravita di Toritto T; Zander T; Driessen C; Specchia G; Waage A; Gimsing P; Mellqvist UH; van Marwijk Kooy M; Minnema M; Mandigers C; Cafro AM; Palmas A; Carvalho S; Spencer A; Boccadoro M; Sonneveld P
    Lancet Haematol; 2020 Jun; 7(6):e456-e468. PubMed ID: 32359506
    [TBL] [Abstract][Full Text] [Related]  

  • 35. P-glycoprotein expression in human plasma cell myeloma: correlation with prior chemotherapy.
    Grogan TM; Spier CM; Salmon SE; Matzner M; Rybski J; Weinstein RS; Scheper RJ; Dalton WS
    Blood; 1993 Jan; 81(2):490-5. PubMed ID: 8093668
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Chemotherapy of multiple myeloma. Review of the recent trials].
    Tribalto M; Arcese W; Colombo R; Pastore S; Franchii A
    Recenti Prog Med; 1981 Aug; 71(2):141-7. PubMed ID: 7031807
    [No Abstract]   [Full Text] [Related]  

  • 37. Comparison of vincristine, carmustine, melphalan, cyclophosphamide, prednisone (VBMCP) and interferon-alpha with melphalan and prednisone (MP) and interferon-alpha (IFN-alpha) in patients with good-prognosis multiple myeloma: a prospective randomized study. Greek Myeloma Study Group.
    Zervas K; Pouli A; Gregoraki B; Anagnostopoulos N; Dimopoulos MA; Bourantas K; Tzilianos M; Barbarousi D; Venetis E; Vyniou N; Maniatis A
    Eur J Haematol; 2001 Jan; 66(1):18-23. PubMed ID: 11168503
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Aggressive combination chemotherapy in multiple myeloma. A multicentre trial. Finnish Leukaemia Group.
    Scand J Haematol; 1985 Aug; 35(2):205-9. PubMed ID: 3901244
    [TBL] [Abstract][Full Text] [Related]  

  • 39. VBAMDex chemotherapy in advanced multiple myeloma.
    Peest D; Schmoll HJ; Schedel I; Glück S; Schumacher K; Deicher H
    Eur J Haematol; 1988 Mar; 40(3):245-9. PubMed ID: 3356240
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Human myeloma in vitro colony growth: interrelationships between drug sensitivity, cell kinetics, and patient survival duration.
    Durie BG; Young LA; Salmon SE
    Blood; 1983 May; 61(5):929-34. PubMed ID: 6831055
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.